Physician profile
Lina Fine
NPI 1316107352
$29,907.62
in general payments reported to CMS, 2019-2025
6 companies · $2,423 in 2025
The $2,423 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,100 · 2022: $10K · 2023: $15K · 2024: $349 · 2025: $2,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $3,210 · Travel and Lodging: $1,907 · Food and Beverage: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,172.00 |
| Consulting Fee | $3,210.00 |
| Travel and Lodging | $1,907.45 |
| Food and Beverage | $1,270.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $26,640.89 | 2021-2025 | Wakix |
| Resmed Corp | $1,925.00 | 2025 | |
| Jazz Pharmaceuticals INC. | $690.17 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $386.67 | 2022 | |
| Horizon Therapeutics Plc | $157.33 | 2023 | Uplizna |
| Idorsia Pharmaceuticals US INC | $107.56 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lina Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.